Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed the day trading at $41.57 down -1.70% from the previous closing price of $42.29. In other words, the price has decreased by -$0.72 from its previous closing price. On the day, 514471 shares were traded.
Ratios:
For a better understanding of CRNX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.07 and its Current Ratio is at 13.07. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 06, 2024, initiated with a Buy rating and assigned the stock a target price of $68.
On January 16, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $50.
On December 21, 2023, Jefferies started tracking the stock assigning a Hold rating and target price of $35.Jefferies initiated its Hold rating on December 21, 2023, with a $35 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 25 ’24 when Betz Stephen F. sold 3,000 shares for $37.26 per share. The transaction valued at 111,780 led to the insider holds 73,298 shares of the business.
Betz Stephen F. sold 3,000 shares of CRNX for $112,950 on Jan 10 ’24. The Chief Scientific Officer now owns 76,298 shares after completing the transaction at $37.65 per share. On Jan 03 ’24, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 14,375 shares for $35.00 each. As a result, the insider received 503,125 and left with 5,911 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 3.30B and an Enterprise Value of 2.80B. Its current Enterprise Value per Revenue stands at 696.89 whereas that against EBITDA is -12.63.
Stock Price History:
Over the past 52 weeks, CRNX has reached a high of $47.58, while it has fallen to a 52-week low of $15.23. The 50-Day Moving Average of the stock is 37.98, while the 200-Day Moving Average is calculated to be 27.89.
Shares Statistics:
Over the past 3-months, CRNX traded about 799.09K shares per day on average, while over the past 10 days, CRNX traded about 816.07k shares per day. A total of 77.93M shares are outstanding, with a floating share count of 71.13M. Insiders hold about 8.72% of the company’s shares, while institutions hold 87.11% stake in the company. Shares short for CRNX as of Feb 15, 2024 were 4.51M with a Short Ratio of 5.65, compared to 5.11M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.76% and a Short% of Float of 7.53%.
Earnings Estimates
Current recommendations for the stock of the company come from 11 analysts. On average, analysts expect EPS of -$0.8 for the current quarter, with a high estimate of -$0.68 and a low estimate of -$0.94, while EPS last year was -$0.85. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.69 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.9 and -$3.83 for the fiscal current year, implying an average EPS of -$3.26. EPS for the following year is -$3.5, with 12 analysts recommending between -$2.77 and -$4.86.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $24.82M in the next fiscal year. The high estimate is $94.69M and the low estimate is $3M. The average revenue growth estimate for next year is up 1,065.30% from the average revenue estimate for this year.
